1394854-52-4

Basic information

• Product Name: GSK J2
• Synonyms: GSK J2;GSK-J2;N-[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanine;SK-J2
• CAS NO: 1394854-52-4
• Molecular Formula: C22H23N5O2
• Molecular Weight: 389.45032
• Mol File: 1394854-52-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GSK J2(CAS DataBase Reference)
• NIST Chemistry Reference: GSK J2(1394854-52-4)
• EPA Substance Registry System: GSK J2(1394854-52-4)

Safety Data

• Hazardous Substances Data: 1394854-52-4(Hazardous Substances Data)

Usage

Description

GSK J2 is the inactive isomer of GSK J1 (G797553), a selective and potent inhibitor of JMJD6 and UTX demethylases. It plays a significant role in various cellular processes and has potential applications in different industries due to its unique properties.

Uses

Used in Pharmaceutical Industry:
GSK J2 is used as a research compound for studying the effects and functions of JMJD6 and UTX demethylases in cellular processes. Its inactive nature allows for the investigation of the role these demethylases play in various biological pathways without the confounding effects of inhibition.
Used in Drug Development:
GSK J2 can be used as a reference compound in the development of new drugs targeting JMJD6 and UTX demethylases. By comparing the properties and effects of active compounds to those of GSK J2, researchers can better understand the potential therapeutic benefits and drawbacks of these new drug candidates.
Used in Cellular and Molecular Biology Research:
GSK J2 serves as a valuable tool in cellular and molecular biology research, particularly in the study of histone demethylation and its role in gene regulation, cell differentiation, and development. Its inactive nature allows researchers to investigate the effects of demethylase inhibition on these processes without directly affecting the demethylases themselves.
Used in Epigenetic Studies:
GSK J2 can be employed in epigenetic studies to explore the role of JMJD6 and UTX demethylases in epigenetic regulation and their potential as therapeutic targets for various diseases, including cancer and neurological disorders. Its inactive isomer status makes it an ideal control compound in these investigations.